NCT lookup

Inclusion Criteria:

* Male and female adult patients 16 year of age or older, who have had a previously confirmed diagnosis of Fabry disease and a history of clinical symptoms of Fabry disease
* Patients who are treatment-naïve or without prior treatment with an approved or experimental therapy for Fabry disease within at least 6 months prior to screening.
* Average score of ≥3 (0=no symptom, 10=symptom as bad as you can imagine) on the participant-defined most-bothersome symptom (among neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain), as measured by the Fabry Disease Patient-Reported Outcome (FD-PRO) at screening.
* Contraception (with double contraception methods) for male and female participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants.
* Weight ≥30 Kg
* A signed informed consent must be provided prior to any study-related procedures.

Exclusion Criteria:

* Any manifestations of Fabry disease that preclude placebo administration.
* History of transient ischemic attack, stroke, myocardial infarction, heart failure, evidence of left ventricular hypertrophy and/or cardiac fibrosis, major cardiovascular surgery, or kidney transplantation.
* History of clinically significant cardiac arrhythmia. Atrial fibrillation that is well controlled on a stable medical regimen for at least 12 months is not an exclusion if the CHA2DS2-VASc score is 0 for males or 1 for females.
* Patients with hepatitis C, HIV, or hepatitis B infection.
* Neuropathic pain in upper or lower extremities, or abdominal pain not related to Fabry disease.
* History of seizures currently requiring treatment.
* Uncontrolled hypertension over the past 12 months prior to screening, or systolic BP \>=150 or diastolic BP \>=100 at screening.
* Estimated glomerular filtration rate \<60 mL/min/1.73m².
* Urine protein to creatinine ratio \>= 1 g/g at screening.
* Presence of severe depression as measured by Beck's Depression Inventory (BDI)-II \>28 and/or a history of an untreated, unstable major affective disorder within 1 year of the screening visit.
* Positive SARS-CoV-2 virus test within 2 weeks of enrollment, or COVID 19 requiring hospitalization within 6 months of enrollment.
* Moderate to severe hepatic impairment.
* History of drug and/or alcohol abuse.
* History of or active hepatobiliary disease.
* Liver enzymes (alanine aminotransferase (ALT)/aspartate aminotransferase (AST)) or total bilirubin \>2 times the upper limit of normal (ULN).
* Initiation of chronic treatment for pain, or change in pain medication regimen, within 3 months prior to randomization.
* Strong or moderate inducers or inhibitors of cytochrome P450 3A within 14 days or 5 half-lives, whichever is longer, prior to randomization.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

• Birmingham, Alabama, United States
• Los Angeles, California, United States
• Orange, California, United States
• Orlando, Florida, United States
• Atlanta, Georgia, United States
• Hawthorne, New York, United States
• Cincinnati, Ohio, United States
• Cleveland, Ohio, United States
• Pittsburgh, Pennsylvania, United States
• Dallas, Texas, United States
• Salt Lake City, Utah, United States
• Fairfax, Virginia, United States
• La Rioja, Argentina
• Quilmes, Argentina
• Parkville, Victoria, Australia
• Vienna, Austria
• Porto Alegre, Rio Grande do Sul, Brazil
• São Paulo, Brazil
• Calgary, Alberta, Canada
• Halifax, Nova Scotia, Canada
• Toronto, Ontario, Canada
• Beijing, China
• Shanghai, China
• Taiyuan, China
• Zhengzhou, China
• Copenhagen, Denmark
• Turku, Finland
• Garches, France
• Hochheim am Main, Germany
• Mainz, Germany
• + 28 more on CT.gov